Osimertinib then chemotherapy for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and agree to the study after an informed consent discussion.
- You must have advanced non-small cell lung cancer (metastatic or not suitable for curative treatment).
- Your tumor must have an EGFR-activating mutation, and exon 20 insertions are not allowed.
- You need to be well enough for treatment (performance status 0–3) and expected to live at least 12 weeks.
- You must have measurable tumors on CT or MRI that can be followed over time.
- You must be able to receive second-line chemotherapy (and meet the timing/platinum+pemetrexed requirements based on when you enroll).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.